ClinicalTrials.gg
Not yet recruitingNCT07631429BRI-ICUUpdated Jun 8, 2026

Body Roundness Index and Mortality in ICU Patients

An observational study in Critical Illness, Obesity & Overweight and Mortality in Intensive Care Units, sponsored by Ondokuz Mayıs University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Primary conditionObesityRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ondokuz Mayıs University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
550
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Obesity by Ondokuz Mayıs University — 4 open to participants now, 4 under way, none of them phase 3. Obesity · Ondokuz Mayıs University.

Started
2026
with 1 other
Observational
3 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Obesity by Ondokuz Mayıs University, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 10th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 10 studies in Obesity by Ondokuz Mayıs University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity by Ondokuz Mayıs University, or all of them as a file.
02

Study summary

This study investigates whether Body Roundness Index (BRI), an anthropometric measure derived from waist circumference and height, can predict mortality in adult intensive care unit (ICU) patients. BRI captures central adiposity and body fat distribution more accurately than Body Mass Index (BMI). In this prospective multicenter cohort study, BRI will be measured at ICU admission and its association with ICU mortality, 28-day mortality, hospital mortality, mechanical ventilation duration, ICU length of stay, and acute kidney injury will be evaluated. The predictive performance of BRI will also be compared with BMI.

Read the detailed description

Body Roundness Index (BRI) is calculated using waist circumference and height, and reflects central adiposity more precisely than BMI. Despite growing evidence supporting BRI as a cardiovascular and metabolic risk predictor in general populations, its prognostic value in critically ill patients remains unexplored.

In this prospective multicenter cohort study, adult patients admitted to participating ICUs will be enrolled. Waist circumference will be measured using a standardized protocol (supine position, iliac crest landmark, end-expiration, inelastic tape, 0.1 cm precision) within 24 hours of ICU admission. BRI will be calculated using the formula: 364.2 - 365.5 × √(1 - ((WC/2π)² / (0.5×height)²)).

The primary outcome is ICU mortality. Secondary outcomes include 28-day mortality, hospital mortality, mechanical ventilation duration, ICU length of stay, and new acute kidney injury (KDIGO stage ≥2). The shape of the BRI-mortality relationship will be assessed using restricted cubic splines. BRI and BMI will be compared head-to-head for discriminative performance. Subgroup analyses will include sepsis patients to evaluate whether BRI resolves the obesity paradox observed with BMI.

03

Conditions studied

  • Critical Illness
  • Obesity & Overweight
  • Mortality in Intensive Care Units
  • Body Composition

Browse trials for

Keywords

  • Body Roundness Index
  • BRI
  • ICU mortality
  • Critical illness
  • Anthropometric measures
  • Central adiposity
  • BMI
  • Obesity paradox
  • Waist circumference
04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 550 is above the median of 115 across 2,159 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Ondokuz Mayıs University is the lead sponsor of 281 studies on the registry; 64 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients admitted to the intensive care units of participating tertiary care centers in Turkey. Enrollment will be conducted prospectively across multiple centers following ethics committee approval at each site.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • ICU admission with expected stay ≥24 hours
  • Waist circumference and height measurable within 24 hours of admission

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • ICU stay \<24 hours
  • Missing or unmeasurable anthropometric data (e.g., severe edema, abdominal wound, morbid obesity precluding measurement)
  • Pregnancy
  • Readmission (only first ICU admission included)
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
550 participants (estimated)
Target follow-up
28 Days
Patient registry
Yes

Groups and cohorts

  • Adult ICU Patients

    Adult patients (≥18 years) admitted to the intensive care unit with an expected stay of ≥24 hours. Waist circumference and height are measured within 24 hours of admission to calculate Body Roundness Index (BRI) and BMI. Patients are followed for ICU mortality, 28-day mortality, hospital mortality, mechanical ventilation duration, ICU length of stay, and acute kidney injury (KDIGO stage ≥2). No intervention is applied; this is a prospective observational cohort.

07

What researchers measure

Primary outcomes

  1. ICU Mortality

    Death occurring during ICU stay, assessed from admission to ICU discharge or death, whichever comes first.

    Time frame: From ICU admission to ICU discharge or death, up to 28 days.

Secondary outcomes

  1. 28-Day Mortality

    All-cause mortality within 28 days of ICU admission.

    Time frame: 28 days from ICU admission.

  2. Hospital Mortality

    Death occurring during hospital stay

    Time frame: From ICU admission to hospital discharge or death, up to 90 days.

  3. Mechanical Ventilation Duration

    Total days of invasive mechanical ventilation during ICU stay.

    Time frame: From ICU admission to ICU discharge, up to 28 days.

  4. ICU Length of Stay

    Total number of days spent in the ICU

    Time frame: From ICU admission to ICU discharge, up to 28 days.

  5. Number of Participants with New Acute Kidney Injury (KDIGO Stage ≥2)

    New AKI development defined as KDIGO stage ≥2 during ICU stay.

    Time frame: From ICU admission to ICU discharge, up to 28 days.

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying published results will be made available upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 6 months after primary results publication, available for 2 years.

Access criteria: Researchers who provide a methodologically sound proposal. Requests should be directed to the corresponding author. Data will be shared after signing a data access agreement.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 12 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 8, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07631429
Responsible party
Ozkul Yilmaz Colak (Lecturer, Department of Internal Medicine, Division of Intensive Care, Ondokuz Mayıs University Faculty of Medicine, Ondokuz Mayıs University) — Principal investigator
First posted
Jun 8, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Özkul Yilmaz Çolak, MD
Contact
ozkulcolak@gmail.com
+905063349266

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion